EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates

Christophe Le Terrier iD, Otávio Hallal Ferreira Raro iD, Alaaeldin Mohamed Saad, Patrice Nordmann iD, Laurent Poirel iD

European Journal of Clinical Microbiology & Infectious Diseases · 2025-02 · 44 (2) · 277-284

DOI: 10.1007/s10096-024-04965-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, online erschienen am 26.11.2024. Verfasst von Christophe Le Terrier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science, University of Fribourg, Che…. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Azabicyclo Compounds, beta-Lactamase Inhibitors, Anti-Bacterial Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Fribourg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Overproduction of the intrinsic chromosomally-encoded AmpC β-lactamase is one of the main mechanisms responsible for broad-spectrum β-lactam resistance in Pseudomonas aeruginosa . Our study aimed to evaluate the in-vitro activity of anti-pseudomonal β-lactam molecules associated with the recently-developed and commercially-available β-lactamase inhibitors, namely avibactam, relebactam and vaborbactam, against P. aeruginosa isolates overproducing their AmpC.

Methods

MIC values of ceftazidime, cefepime, meropenem, imipenem and ceftolozane with or without β-lactam inhibitor were determined for 50 AmpC-overproducing P. aeruginosa clinical isolates. MIC breakpoints for resistance were retained at 8 mg/L for β-lactams and β-lactam/β-lactamase inhibitor combinations containing ceftazidime, cefepime and meropenem, while 4 mg/L was used for those containing imipenem and ceftolozane. The concentration of all β-lactamases inhibitors was fixed at 4 mg/L, except for vaborbactam (8 mg/L).

Results

The rates of isolates not being resistant to ceftazidime, cefepime, meropenem, imipenem and ceftolozane were found at 12%, 22%, 34%, 8% and 74%, respectively. When combined with avibactam, those rates increased to 60%, 62%, 60%, 46%, and 80%, respectively. The highest rates were found with relebactam-based combinations, being 76%, 64%, 66%, 76% and 84%, respectively. By contrast, associations with vaborbactam did not lead to significantly increased “non-resistance” rates.

Conclusion

Our results showed that all combinations including relebactam led to higher “non-resistance” rates against AmpC-overproducing P. aeruginosa clinical isolates. The best activity was achieved by combining ceftolozane and relebactam, that might therefore be considered as an excellent clinical alternative against AmpC overproducers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaAzabicyclo Compoundsbeta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-LactamasesBoronic AcidsBacterial Proteinsbeta-LactamsMicrobial Sensitivity TestsHumansPseudomonas Infectionsbeta Lactam Antibiotics

Stichwörter der Autor:innen

Pseudomonas aeruginosaAmpC overproducingAntimicrobial resistanceAvibactamCarbapenemCeftolozaneCephalosporinsRelebactamVaborbactamβ-lactamases inhibitors

Substanzen

Azabicyclo Compoundsbeta-Lactamase InhibitorsAnti-Bacterial Agentsavibactamrelebactambeta-LactamasesAmpC beta-lactamasesvaborbactamBoronic AcidsBacterial Proteins

Autor:innen und Institutionen

  • Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science, University of Fribourg, Chemin du Musée 18, Fribourg, CH-1700, Switzerland.
  • Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland.
  • Department of Zoonoses, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.
  • Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
  • Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science, University of Fribourg, Chemin du Musée 18, Fribourg, CH-1700, Switzerland. laurent.poirel@unifr.…
  • Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland. laurent.poirel@unifr.ch.

ORCID-Profile: Christophe Le Terrier, Otávio Hallal Ferreira Raro, Patrice Nordmann, Laurent Poirel

Förderung

  • University of Fribourg

Zitieren

APA

Le Terrier, C., Raro, O. H. F., Saad, A. M., Nordmann, P., & Poirel, L. (2025). In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates. European Journal of Clinical Microbiology & Infectious Diseases, 44(2), 277-284. https://doi.org/10.1007/s10096-024-04965-x

Vancouver

Le Terrier C, Raro OHF, Saad AM, Nordmann P, Poirel L. In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates. European Journal of Clinical Microbiology & Infectious Diseases. 2025;44(2):277-284. doi:10.1007/s10096-024-04965-x

BibTeX
@article{LeTerrier2025,
  author = {Le Terrier, Christophe and Raro, Otávio Hallal Ferreira and Saad, Alaaeldin Mohamed and Nordmann, Patrice and Poirel, Laurent},
  title = {In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2025},
  volume = {44},
  number = {2},
  pages = {277--284},
  doi = {10.1007/s10096-024-04965-x}
}
Kostenlos starten →